Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users

AIDS

Volumn 15, Issue 13, 2001, Pages 1707-1715

  Celentano, David D ^a   Galai, Noya ^a,c   Sethi, Ajay K ^a   Shah, Nina G ^a   Strathdee, Steffanie A ^a   Vlahov, David ^a,b,d   Gallant, Joel E ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d NEW YORK ACADEMY OF MEDICINE   (United States)

Author keywords

Health care access; Highly active antiretroviral therapy; Injection drug users

Indexed keywords

ANTIRETROVIRUS AGENT; METHADONE;

ANTIVIRAL ACTIVITY; ARTICLE; FEMALE; HEALTH CARE ACCESS; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; METHADONE; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 0035823013     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109070-00015     Document Type: Article

References (28)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection
4. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
5. Variations in the care of HIV-infected adults in the United States. Results from the HIV Cost and Services Utilization Study
6. Self-reported antiretroviral therapy in injection drug users
7. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society- USA panel
8. Barriers to use of free antiretroviral therapy in injection drug users
9. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: Description of methods and characteristics of participants
10. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel
11. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
12. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
13. Strategies for long-term success in the treatment of HIV infection
14. The care of HIV-infected adults in the United States
15. Antiretroviral treatment and progression to AIDS in HIV sero-converters from different risk groups
16. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons
17. National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups
18. Intravenous drug use and the immune system
19. Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus
20. Protease inhibitors in the homeless
21. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine
22. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
23. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival
24. A model for the delivery of care for HIV-positive clients
25. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival
26. Protease inhibitors (PI) in the HIV+ homeless and marginally housed (H/M): Good adherence but rarely prescribed
27. Clinical experience and choice of drug therapy for human immunodeficiency virus disease
28. Ability of primary care physicians to recognize physical findings associated with HIV infection